无利巴韦林的雷迪帕韦联合索磷布韦治疗肝移植受者HCV感染
这项回顾性研究分析了75例肝移植后基因1型HCV感染患者,采用雷迪帕韦/索磷布韦联合方案(不含利巴韦林)治疗。意向性分析显示SVR12达95.9%,仅第8周可检测到病毒载量预测治疗失败。作者认为该方案在肝移植受者中具有优异的SVR结局和良好的安全性、耐受性,尽管治疗指南推荐联用利巴韦林。
要点
- 肝移植后基因1型HCV感染患者使用雷迪帕韦/索磷布韦(无利巴韦林)的SVR12为95.9%。
- 单因素logistic回归中,仅第8周可检测到病毒载量预测未获得SVR。
- 作者认为该方案结局优异且安全性、耐受性良好,尽管指南推荐联用利巴韦林。
核心结论
- 作者认为,尽管治疗指南推荐使用利巴韦林,但无利巴韦林的雷迪帕韦/索磷布韦在肝移植后HCV感染受者中证实了优异的SVR结局和良好的安全性、耐受性。
研究设计与样本
- 回顾性研究,纳入75例肝移植后接受无利巴韦林的雷迪帕韦联合索磷布韦治疗的患者,以意向性治疗(ITT)方式分析SVR队列间差异及SVR预测因素。
主要发现
- 2014年10月至2015年8月本中心共408例基因1型HCV患者接受雷迪帕韦/索磷布韦治疗,其中73例为肝移植后患者,移植后中位治疗时间为2.9年。
- 雷迪帕韦/索磷布韦获得95.9%的SVR12。
- 队列中非裔美国人占28.8%,63%的患者既往接受过治疗(包括13.7%既往接受直接抗病毒药物治疗),仅2.7%存在移植物肝硬化复发,90.4%使用以钙调神经磷酸酶抑制剂为基础的免疫抑制治疗,约82%为慢性肾脏病(CKD)2期或3期。
- 单因素logistic回归中,仅第8周可检测到病毒载量预测未获得SVR。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ledipasvir and sofosbuvir is a well-tolerated regimen with high sustained virological response (SVR) rates in pre-liver transplant patients infected with chronic hepatitis C virus (HCV), but data in liver transplant recipients outside of clinical trials is limited. AIM: To address this knowledge gap and assess SVR rates without the use of ribavirin in liver transplant recipients METHODS: This is a retrospective study examining the treatment of 75 post-liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Differences between SVR cohorts and predictors of SVR were analysed in an intention-to-treat (ITT) fashion. RESULTS: A total of 408 genotype 1, HCV patients were treated with ledipasvir/sofosbuvir from October 2014 to August 2015 at our centre. Seventy-three patients were post-liver transplant and were treated with a median of 2.9 years from transplant. Ledipasvir/sofosbuvir achieved an SVR12 of 95.9%. African Americans made up 28.8% of the cohort. Sixty-three per cent of patients were treated previously, including 13.7% of patients previously treated with direct-acting antivirals. Only 2.7% had recurrent allograft cirrhosis, and the majority (90.4%) was on calcineurin inhibitor based immunosuppressive therapy. Approximately 82% of patients had chronic kidney disease (CKD) stage 2 or 3. In univariate logistic regression, only detectable week 8 viral load was predictive of failure to achieve SVR. CONCLUSION: Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post-liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin.
引用
- Pillai AA, Maheshwari R, Vora R, et al. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017. PMID: 28382751. doi:10.1111/apt.14059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。